Literature DB >> 24573547

Desmoid tumor mimicking GIST recurrence.

Nina Nandy1, Wendy Garvin, Thalia L Mesologites, Joel S Silver, Constantin A Dasanu.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24573547     DOI： 10.1007/s12029-014-9592-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  20 in total

1.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene.

Authors:  S Hirota; T Okazaki; Y Kitamura; P O'Brien; L Kapusta; I Dardick
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

2.  The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma.

Authors:  J A Carney; S G Sheps; V L Go; H Gordon
Journal:  N Engl J Med       Date:  1977-06-30       Impact factor: 91.245

Review 3.  Desmoids in familial adenomatous polyposis.

Authors:  S K Clark; R K Phillips
Journal:  Br J Surg       Date:  1996-11       Impact factor: 6.939

Review 4.  Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles.

Authors:  J J Nuyttens; P F Rust; C R Thomas; A T Turrisi
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

5.  Mesenteric desmoid tumor developing on the site of an excised gastrointestinal stromal tumor.

Authors:  Mohammad Khan; George Bozas; Justin Cooke; Kevin Wedgwood; Anthony Maraveyas
Journal:  Rare Tumors       Date:  2010-06-30

6.  The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population.

Authors:  J J Reitamo; P Häyry; E Nykyri; E Saxén
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

7.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.